This Is MS Multiple Sclerosis Knowledge & Support Community

Multiple sclerosis drug MIS416 benefits from compassionate use in progressive MS

Innate Immunotherapeutics drug candidate for secondary progressive multiple sclerosis continues to benefit patients being treated on compassionate grounds in New Zealand.

It is also providing the company with strong data and results from use of MIS416 which show the majority of patients in the program are benefitting from its use.

Of the 24 patients using drug candidate MIS416, 15 were previously subjects in the company’s Phase 1B/2A trial and had requested ongoing access to the drug after completion of the trial...... Read More - http://www.ms-uk.org/MIS416

Interesting to read about this other than the information was released by an investors group as opposed to a medical journal.

There is really nothing out there to help SPMS patients and the initial Phase 1 results do seem encouraging. Note that this drug appears to reduce the symptoms of MS as opposed to doing anything for the disease...at least to what is known at this point. Of course long term safety is not known but patients who are declining with SPMS may not be too concerned about that in their situation.